Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 2/2020

01-04-2020 | Type 2 Diabetes | Original Article

MACF1 gene variant rs2296172 is associated with T2D susceptibility in Mizo population from Northeast India

Authors: Freda Lalrohlui, Varun Sharma, Indu Sharma, Hemender Singh, Guneet Kour, Surbhi Sharma, Yuman, John Zohmingthanga, Vanlalhruaii, Ekta Rai, Vinod Singh, Nachimuthu Senthil Kumar, Swarkar Sharma

Published in: International Journal of Diabetes in Developing Countries | Issue 2/2020

Login to get access

Abstract

Aim

Microtubule actin cross-linking factor 1 (MACF1) has been identified as a type 2 diabetes (T2D) candidate gene, and variant rs2296172 of the gene was found associated with T2D in multiple populations. However, it has never been explored in Mizo population. The aim of the present study was to replicate the association of variant rs2296172 of MACF1 gene with T2D in Mizo population of Northeast India.

Methodology

The variation was genotyped using TaqMan allele discrimination assay in 755 individuals (425 cases and 330 healthy controls), belonging to the Mizo population.

Results

The variant rs2296172 MACF1 was found to be significantly associated with T2D (p value = 0.001) in Mizo population group with an observed odds ratio of 1.8 [1.3–2.8] at 95% CI after correction with age, gender and BMI.

Conclusion

This study is the first replication report from Northeast India, showing variant rs2296172 of MACF1 gene associated with T2D in Mizo population. This independent study highlights MACF1 as a candidate gene for T2D in Asian Indian populations, suggesting it is critical to evaluate the variant rs2296172 in other distinct endogamous Indian population cohorts.
Appendix
Available only for authorised users
Literature
7.
go back to reference Sharma V, Sethi I, Sharma I, Singh G, Mahajan A, Angural A, et al. Replication of MACF1 gene variant rs2296172 with type 2 diabetes susceptibility in the Bania population group of Punjab, India. Int J Diabetes Dev Ctries. 2017;38:387–90. https://doi.org/10.1007/s13410-017-0598-6. Sharma V, Sethi I, Sharma I, Singh G, Mahajan A, Angural A, et al. Replication of MACF1 gene variant rs2296172 with type 2 diabetes susceptibility in the Bania population group of Punjab, India. Int J Diabetes Dev Ctries. 2017;38:387–90. https://​doi.​org/​10.​1007/​s13410-017-0598-6.
12.
go back to reference Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Control Clin Trials. 1997;18:274.CrossRef Dupont WD, Plummer WD. PS power and sample size program available for free on the Internet. Control Clin Trials. 1997;18:274.CrossRef
15.
go back to reference Yang H, Duckett CS, Lindsten T. iPABP, an inducible poly(a)-binding protein detected in activated human T cells. Mol Cell Biol. 1995;15(12):6770–6.CrossRef Yang H, Duckett CS, Lindsten T. iPABP, an inducible poly(a)-binding protein detected in activated human T cells. Mol Cell Biol. 1995;15(12):6770–6.CrossRef
21.
go back to reference Kodama A, Karakesisoglou I, Wong E, Vaezi A, Fuchs E. ACF7: an essential integrator of microtubule dynamics. Cell. 2003;115(3):343–54.CrossRef Kodama A, Karakesisoglou I, Wong E, Vaezi A, Fuchs E. ACF7: an essential integrator of microtubule dynamics. Cell. 2003;115(3):343–54.CrossRef
Metadata
Title
MACF1 gene variant rs2296172 is associated with T2D susceptibility in Mizo population from Northeast India
Authors
Freda Lalrohlui
Varun Sharma
Indu Sharma
Hemender Singh
Guneet Kour
Surbhi Sharma
Yuman
John Zohmingthanga
Vanlalhruaii
Ekta Rai
Vinod Singh
Nachimuthu Senthil Kumar
Swarkar Sharma
Publication date
01-04-2020
Publisher
Springer India
Keyword
Type 2 Diabetes
Published in
International Journal of Diabetes in Developing Countries / Issue 2/2020
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-019-00788-1

Other articles of this Issue 2/2020

International Journal of Diabetes in Developing Countries 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine